Table 3.
Comparison of the performance metrics of WGS-AST on Illumina and ONT assemblies, by antimicrobial.
| Antimicrobial | CA | VME | ME | n | |||
|---|---|---|---|---|---|---|---|
| Illumina | ONT | Illumina | ONT | Illumina | ONT | ||
| Amikacin | 80% | 83% | 23% | 20% | 19% | 16% | 163 |
| Aztreonam | 91% | 92% | 9% | 6% | 12% | 14% | 180 |
| Cefazolin | 84% | 84% | 22% | 20% | 0% | 6% | 68 |
| Cefepime | 85% | 83% | 16% | 21% | 12% | 7% | 173 |
| Cefotaxime | 96% | 95% | 4% | 4% | 0% | 10% | 107 |
| Ceftazidime | 89% | 93% | 10% | 5% | 14% | 14% | 181 |
| Ceftazidime-avibactam | 97% | 96% | 6% | 35% | 3% | 1% | 175 |
| Ceftriaxone | 96% | 96% | 4% | 2% | 3% | 7% | 79 |
| Ciprofloxacin | 95% | 88% | 3% | 12% | 10% | 12% | 181 |
| Doripenem | 84% | 83% | 22% | 22% | 8% | 11% | 164 |
| Ertapenem | 94% | 91% | 7% | 6% | 4% | 16% | 181 |
| Gentamicin | 93% | 88% | 8% | 8% | 6% | 15% | 171 |
| Imipenem | 84% | 79% | 6% | 5% | 31% | 44% | 94 |
| Imipenem-relebactam | 97% | 97% | 21% | 21% | 1% | 1% | 91 |
| Levofloxacin | 90% | 85% | 9% | 14% | 11% | 18% | 181 |
| Meropenem | 84% | 80% | 3% | 5% | 31% | 37% | 90 |
| Meropenem-vaborbactam | 97% | 95% | 21% | 36% | 1% | 1% | 91 |
| Piperacillin-tazobactam | 90% | 84% | 11% | 21% | 7% | 2% | 168 |
| Sulfamethoxazole-trimethoprim | 80% | 80% | 11% | 8% | 30% | 33% | 167 |
| Tetracycline | 81% | 82% | 30% | 30% | 12% | 10% | 79 |
| Ticarcillin-clavulanic acid | 92% | 95% | 9% | 5% | 0% | 0% | 101 |
| Tobramycin | 94% | 92% | 4% | 6% | 7% | 10% | 173 |
CA: Categorical agreement, VME: Very major error, ME: Major error, n: number of evaluated species-antimicrobial pairs.